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U.S. dollars. Incremental cost-effectiveness ratios (ICERs) were calculated compar-
ing the least costly alternative to the next most costly strategy. Deterministic and
probabilistic sensitivity analyses were conducted. RESULTS: Ranibizumab demon-
strated superior efficacy relative to other strategies in both BRVO and CRVO but was
most costly ($26,732 and $32,850; BRVO and CRVO, respectively). Other strategy
costs ranged from $10,622 (observation in BRVO) to $16,090 (dexamethasone intra-
vitreal implant in CRVO patients). QALYs were greatest for ranibizumab (6.75 and
6.10; BRVO and CRVO, respectively) compared to a range of 4.88 (observation in
CRVO) to 5.93 (laser in BRVO). Dexamethasone intravitreal implant was dominated
in BRVO as was no treatment in CRVO. ICERs for ranibizumab were favorable
($19,270/QALY vs laser in BRVO; $34,204/QALY vs dexamethasone intravitreal im-
plant in CRVO). At a threshold of $50,000/QALY, probabilistic analyses suggested
ranibizumab to be cost effective in 99.7% (BRVO) and 88.3% (CRVO) of simulations.
CONCLUSIONS: In patients with ME secondary to BRVO or CRVO, ranibizumab is a
cost-effective treatment alternative.
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EVALUATION OF HEALTH UTILITY IN PATIENTS WITH RETINAL VEIN
OCCLUSION
Balshaw RF1, Gonder J2, Ferreira A3, Zaour N4, Blouin J4, Barbeau M4
1Syreon Corp, Vancouver, BC, Canada, 2St. Joseph’s Health Care, London, ON, Canada, 3Novartis
Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
OBJECTIVES: Retinal vein occlusion (RVO) is the second most common vascular
disorder of the retina, affecting approximately 28,000 new patients every year in
Canada, but little is known about their health utility. A Canadian Observational
Utility Study was conducted to estimate utility values for RVO patients with differ-
ent levels of visual acuity (VA). METHODS: A total of 202 participants with RVO,
where 37% had CRVO and 63% had BRVO, were enrolled from 20 sites across Can-
ada. Participantss had RVO in either their best-seeing eye (17%) or worse-seeing eye
(83%). Spectacle corrected VA was measured and patient health utility was col-
lected using the Health Utilities Index questionnaire (HUI3). VA was recorded as a
fraction (Snellen Score) and the value of this fraction was expressed as logMAR. A
linear regression model was used to predict utility values from logMAR in the
affected eye adjusting for key clinical covariates (age, duration of disease, logMAR
in fellow eye). The baseline characteristics of participants from randomized con-
trolled clinical trials (BRAVO, CRUISE) were used to generate predicted health util-
ities relevant in the context of these studies. RESULTS: For the 202 participants
(ages 39 to 92, median 72) the mean (SD) HUI utility value was 0.80 (0.20), ranging
from 0.18 to 1 (n169) and logMAR score was 0.62 (0.42), ranging from 0 to 1.60
(n202). The correlation between VA and utility was significant (r -0.21, p0.004,
n169) and the regression model indicated that a one unit increase in logMAR
score was associated with 0.085 unit decrease in utility. Based on the regression
model, HUI-based utilities decrease from 0.87 (logMAR -0.15) to 0.74 (logMAR 1.45)
for typical patients in the randomized studies (mean age67, logMAR fellow
eye0.09, disease duration3.4 months). CONCLUSIONS: RVO is a debilitating
ophthalmologic condition leading to reduced health utility with worsening of vi-
sual acuity.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, many moderate and severe psoriasis patients
remain on these therapies. This analysis aims to assess levels of satisfaction and
quality of life in a biologic-eligible patient population currently receiving tradi-
tional systemic therapy. METHODS: Data were extracted from the Adelphi Real
World Psoriasis Disease-Specific Programme® (DSP), a cross-sectional survey of
dermatologists and their patients conducted in early 2011 in France, Germany,
Italy, Spain and the UK. Each dermatologist completed a comprehensive patient
record form (PRF) for their seven most recently seen psoriasis patients who met the
inclusion criteria. Patients were also invited to fill out a self-completion question-
naire, which included questions on satisfaction with treatment and various vali-
dated Health Related Quality of Life (HRQoL) instruments (EQ5D and DLQI). Patients
inclusion criteria were based on being eligible to receive biologic therapy; defined
by Body Surface Area ever exceeding 10%, ever having moderate or severe disease
(in the opinion of the physician), or ever having received a traditional systemic or
biologic treatment. RESULTS: Patient reported satisfaction levels show 58.7%
(n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with current systemic
treatment. Analyses also suggested lower QoL amongst dissatisfied patients (all
reported figures have P-values 0.01; mean differences (MD) shown account for
confounding factors; age, severity and BSA). EQ-5D and DLQI scores indicated
poorer QoL amongst dissatisfied systemic patients, SAT 0.841 v DIS 0.672 (MD 0.124)
and SAT 5.14 v DIS 9.68 (MD 3.25), respectively. CONCLUSIONS: The analysis con-
ducted indicates that a number of patients remain dissatisfied with systemic treat-
ment. This dissatisfaction is associated with lower QoL, measured by both generic
and disease specific instruments. There is scope for additional investigation to
determine if alternate treatment pathways could improve both treatment satisfac-
tion and QoL for this patient group.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, there remain barriers to biologic uptake in
many moderate and severe psoriasis patients. This analysis assesses the level of
treatment satisfaction with patient burden, namely work/activity impairment and
emotional wellbeing, in 445 patients currently receiving traditional systemic ther-
apy who are eligible for, but not receiving, biologic therapy. METHODS: Data were
extracted from the Adelphi Real World Psoriasis Disease-Specific Programme®, a
cross-sectional survey of 292 dermatologists and their patients conducted in early
2011 in France, Germany, Italy, Spain and the UK. Each dermatologist completed
patient record forms for their seven most recently seen patients. Patients were
invited to complete a questionnaire, including questions on satisfaction and vali-
dated instruments WPAI (Work Productivity and Activity Impairment) & PHQ9 (per-
sonal health questionnaire). Patient inclusion criteria were based on being eligible
to receive biologic therapy defined by: Body Surface Area ever exceeding 10%, ever
having moderate or severe disease (physician assessment), or ever having received
a traditional systemic or biologic treatment.RESULTS: Patient reported satisfaction
levels show 58.7% (n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with
current treatment. Results from the WPAI questionnaire (n177) implied worse
average results for those dissatisfied with current treatment, DIS 30.40 v SAT 17.12
(Mean Difference (MD) -10.53). PHQ9 (n442) also found worse outcomes for dis-
satisfied patients; SAT 3.57 v DIS 6.01 (MD -1.94). All reported figures have P-values
0.05; MD incorporate confounding factors; age, severity and BSA. CONCLUSIONS:
This analysis provides insight into the divergence in burden of disease amongst
psoriasis patients, with patients dissatisfied with current systematic regimen suf-
fering greater implied levels of burden than satisfied patients. There is scope to
develop this further to better understand the implications of treatment dissatis-
faction in this population.
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OBJECTIVES: Patient-relevant endpoints play an important role in Health Technol-
ogy Assessment (HTA). There is a need to prioritize these endpoints according to
patients’ preferences. Our aim was to investigate how glaucoma patients prioritize
different aspects of their treatment including patient-relevant endpoints.
METHODS: The study included a feasibility test and the completion of a specific
questionnaire at the ophthalmology clinic of Bonn. Patients rated the importance
of different aspects of glaucoma treatment by a pairwise comparison. Relative
weights were generated for each aspect by Analytic Hierarchy Process (AHP), a
multi-criteria decision analysis method using matrix algebra. . Additionally the
EQ-5D was applied to stratify the patients into subgroups according to their stated
utility. RESULTS: The AHP yielded the following results (Weight, Mean, SD, CI) by
downwards order: 1. Autonomy (0.394, 0.371  0.145, 0.311 - 0.431), subdivided in
household chores (0.239, 0.275  0.258, 0.168 - 0.381) and outdoor mobility (0.761,
0.725 0.258, 0.619 - 0.832). 2. Reading and seeing details (0.229, 0.212 0.123, 0.161
- 0.263). 3. Darkness and glare (0.153, 0.165 0.111, 0.119 - 0.211). 4. Peripheral vision
(0.089, 0.085 0.058, 0.061 - 0.109). 5. Side effects (0.088, 0.115 0.131, 0.060 - 0.168),
and 6. Treatment-related burden (0.047, 0.052  0.06, 0.027 - 0.076). The observed
inconsistency reached a consistency ratio of 0.04 and did not exceed the limit of 0.1.
Subgroup analyses according to the EQ-5D stratification showed adaptation effects
and loss aversion. CONCLUSIONS: AHP can be used in HTA to give a quantitative
dimension to patients’ preferences for treatment aspects. Preference elicitation
could provide important information at various stages of HTA and challenge opin-
ions on the importance of treatment aspects or endpoints.
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OBJECTIVES: Empirical evidence for the efficacy of drugs and therapeutic proce-
dures has become crucial for reimbursement and for use in praxis. Beyond that,
assessment of patient benefit from the patient’s perspective is of particular rele-
vance. The PBI for skin diseases is a validated instrument developed to measure
patient-relevant benefits in dermatology. So far, no specific validation data on such
an instrument for psoriasis have been published. Objective of this study was the
validation of PBI specifically for psoriasis treatment. METHODS: Patient-relevant
treatment needs were recorded with the “Patient Needs Questionnaire” (PNQ) and
patient benefits from treatment were assessed using the “Patient Benefit Question-
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